XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2

Revenue (Tables)

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Total Revenue by Product and by U.S versus Rest of World

The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):

			Three months ended September 30,
			2021																					2020
(in millions)			U.S.						RoW						Total									U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	68.2					$	11.2					$	79.4								$	72.0					$	8.5					$	80.5
Tumor Profiling			21.4						11.5						32.9									14.4						2.6						17.0
Prenatal			23.5						0.1						23.6									16.5						0.1						16.6
Pharmacogenomics			24.1						—						24.1									11.9						—						11.9
Autoimmune			7.3						—						7.3									9.1						—						9.1
Other			—						—						—									0.6						—						0.6
Total molecular diagnostic revenue			144.5						22.8						167.3									124.5						11.2						135.7
Pharmaceutical and clinical services revenue			—						—						—									9.5						—						9.5
Total revenue			$	144.5					$	22.8					$	167.3								$	134.0					$	11.2					$	145.2
			Nine months ended September 30,
			2021																					2020
(in millions)			U.S.						RoW						Total									U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	207.1					$	34.4					$	241.5								$	188.2					$	17.4					$	205.6
Tumor Profiling			63.9						30.5						94.4									33.7						7.5						41.2
Prenatal			76.3						0.4						76.7									53.2						0.3						53.5
Pharmacogenomics			64.3						—						64.3									40.8						—						40.8
Autoimmune			28.2						—						28.2									26.8						—						26.8
Other			—						0.5						0.5									1.6						—						1.6
Total molecular diagnostic revenue			439.8						65.8						505.6									344.3						25.2						369.5
Pharmaceutical and clinical services revenue			24.2						—						24.2									29.0						3.9						32.9
Total revenue			$	464.0					$	65.8					$	529.8								$	373.3					$	29.1					$	402.4

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:

			Nine months ended September 30,
(in millions)			2021									2020
Deferred revenues - beginning balance			$	32.7								$	3.6
Revenue recognized			(30.3)									(8.4)
Prepayments			10.1									37.1
Divestitures			$	(1.0)								$	—
Deferred revenues - ending balance			$	11.5								$	32.3

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration